Tissue Regeneration Technologies awarded new patents for biofilm elimination and reproductive health
August 25, 2010 (Woodstock, Georgia) – Tissue Regeneration Technologies, LLC (TRT), a Woodstock, GA based medical technology company, recently received the rights to two new patents for its SoftWave™ technology portfolio.
The two patents, a method of preventing and eliminating biofilms (U.S. Patent No. 7,497,834) and a therapeutic stimulation of genital tissue to combat infertility or impotence (U.S. Patent No. 7,601,127), exemplify the growth and expansion of TRT's SoftWave™ technology.
August 25, 2010 (Woodstock, Georgia) – Tissue Regeneration Technologies, LLC (TRT), a Woodstock, Georgia medical technology company, recently received the rights to a new patent to bolster its SoftWave™ technology portfolio. The patent covers a method of reattaching damaged soft tissue to bone.
Surgical procedures of reattaching damaged tissues such as ligaments and tendons to bone typically involve sutures or screws, and success is not guaranteed. Transplant cadaver ligaments are used when a person's own are unlikely to reattach under normal surgical procedures. Furthermore, time is of the essence in such procedures; generally, more time elapsed before or after operation results in lower success rates.
TRT's new patent (U.S. Patent No. 7,594,930) involves administering shock waves to a surgically anchored tissue in order to increase procedure reliability and decrease healing time. The new method is effective with either a patient's own or transplant tissues. The treatment is used whenever a ligament or muscle detaches from bone, typically because of severe traumatic injury.
Tissue Regeneration Technologies, LLC awarded another patent to expand its SoftWave™ technology portfolio.
WOODSTOCK, GA. -- Tissue Regeneration Technologies, LLC (TRT), a Woodstock, GA. based medical technology company, announced Monday it received another patent award to expand its innovative unfocused shock wave technology portfolio.
The company’s newest patent award (U.S. Patent 7,695,443) covers a novel device for generating shock waves. TRT’s patent portfolio increases to 15 granted patents and 20 published patent applications. TRT retains rights to its expanding intellectual property portfolio as an exclusive owner and exclusive licensee.
John Warlick, Chief Executive Officer of TRT, stated the recent patent award is aimed at further increasing the effectiveness and reliability of its SoftWave™– unfocused shock wave– technologies.